Clinical Trials

Overview

About this study

The purpose of this story is to identify key radiographic variables that are predictive of symptomatic improvement in those patients undergoing endobronchial valve placement.  

Symptomatic management of emphysema continues to be a difficult task by medical therapy alone. Bronchoscopic lung volume reduction (BLVR), utilizing minimal invasive placement of endobronchial valves, has emerged as a new therapeutic option. Early trial data demonstrated statistically and clinically significant improvement in FEV1, 6 minutes walk (6MW) distance, and quality of life.  However, following the procedure, there are currently no good early predictors of symptomatic benefit. Often, patients wait several months to know if valve placement was successful. This is not only inconvenient to the patient, but it can also increase adverse effects when a non-functional medical device remains in place.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Participating Mayo Clinic locations

More information